Literature DB >> 27092659

Colorectal Cancer Liver Metastases: Diagnostic Performance and Prognostic Value of PET/MR Imaging.

Dong Ho Lee1, Jeong Min Lee1, Bo Yun Hur1, Ijin Joo1, Nam-Joon Yi1, Kyung-Suk Suh1, Keon Wook Kang1, Joon Koo Han1.   

Abstract

Purpose To evaluate the diagnostic performance of combined positron emission tomography (PET) and magnetic resonace (MR) imaging (hereafter, PET/MR imaging) in the detection of liver metastases and to assess its prognostic value in patients with colorectal cancer liver metastases (CRLMs). Materials and Methods Institutional review board approval was obtained for this retrospective study, with waiver of informed consent. A total of 55 patients with 98 CRLMs who underwent PET/MR imaging and multidetector computed tomography (CT) between January 2013 and June 2014 comprised the study population. Of these patients, 34 underwent hepatic resection, 18 of whom also underwent neoadjuvant chemotherapy (NAC). Two board-certificated radiologists independently assessed the four image sets (ie, multidetector CT, whole-body PET, MR imaging with a liver-specific contrast agent [hereafter, EOB MR imaging], and PET/MR imaging). To compare the diagnostic performance of each imaging modality, jackknife alternative free-response receiver operating characteristic and generalized estimating equations were used. To assess prognostic value, recurrence-free survival of the 18 patients who underwent NAC followed by hepatic resection was analyzed by using the Kaplan-Meier method and log-rank test. Results The reader-averaged figure of merit of PET/MR imaging was significantly higher than that of either multidetector CT (P = .003) or PET (P = .020) in the detection of CRLMs. However, no significant difference was observed between figure of merit for PET/MR imaging and that for EOB MR imaging (P = .231). After NAC, six of the 18 patients had isometabolic CRLMs on PET images, and 12 patients had hypermetabolic CRLMs. The 1-year recurrence-free survival rate was 80% in patients with isometabolic CRLMs and 14% in patients with hypermetabolic CRLMs, showing a significant difference (P = .026). Conclusion PET/MR imaging can yield significantly higher diagnostic performance in the detection of CRLMs when compared with the performance of multidetector CT or PET. However, no significant difference in diagnostic performance was observed between PET/MR imaging and EOB MR imaging. In addition, the degree of fluorodeoxyglucose uptake after NAC may have the potential to yield prognostic information for recurrence-free survival after hepatic resection. (©) RSNA, 2016 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27092659     DOI: 10.1148/radiol.2016151975

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  12 in total

1.  Impact of Tissue Classification in MRI-Guided Attenuation Correction on Whole-Body Patlak PET/MRI.

Authors:  Mingzan Zhuang; Nicolas A Karakatsanis; Rudi A J O Dierckx; Habib Zaidi
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

2.  Diagnostic performance of PET/MR in the evaluation of active inflammation in Crohn disease.

Authors:  Onofrio Antonio Catalano; Vincent Wu; Umar Mahmood; Alberto Signore; Mark Vangel; Andrea Soricelli; Marco Salvatore; Debra Gervais; Bruce R Rosen
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

3.  Magnetic resonance with diffusion-weighted imaging improves assessment of focal liver lesions in patients with potentially resectable pancreatic cancer on CT.

Authors:  Sun Kyung Jeon; Jeong Min Lee; Ijin Joo; Dong Ho Lee; Su Joa Ahn; Hyunsik Woo; Myoung Seok Lee; Jin-Young Jang; Joon Koo Han
Journal:  Eur Radiol       Date:  2018-01-19       Impact factor: 5.315

Review 4.  Diagnostic performance of [18F]-FDG PET/MR in evaluating colorectal cancer: a systematic review and meta-analysis.

Authors:  Seyed Ali Mirshahvalad; Ricarda Hinzpeter; Andres Kohan; Reut Anconina; Roshini Kulanthaivelu; Claudia Ortega; Ur Metser; Patrick Veit-Haibach
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-06-16       Impact factor: 10.057

Review 5.  KSNM60 in Clinical Nuclear Oncology.

Authors:  Seung Hwan Moon; Young Seok Cho; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2021-08-31

Review 6.  [Hybrid imaging of the abdomen and pelvis. German version].

Authors:  Krista Elise Suarez-Weiss; Alexander Herold; Debra Gervais; Edwin Palmer; Bárbara Amorim; Joseph D King; Li Weier; Tajmir Shahein; Hanna Bernstine; Liran Domachevsk; Lina Garcia Cañamaque; Lale Umutlu; Ken Herrmann; David Groshar; Onofrio A Catalano
Journal:  Radiologe       Date:  2020-05       Impact factor: 0.635

7.  18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine.

Authors:  Julian Kirchner; Lino M Sawicki; Cornelius Deuschl; Johannes Grüneisen; Karsten Beiderwellen; Thomas C Lauenstein; Ken Herrmann; Michael Forsting; Philipp Heusch; Lale Umutlu
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

8.  Radiomics of liver MRI predict metastases in mice.

Authors:  Anton S Becker; Marcel A Schneider; Moritz C Wurnig; Matthias Wagner; Pierre A Clavien; Andreas Boss
Journal:  Eur Radiol Exp       Date:  2018-05-28

9.  Management of indeterminate hepatic nodules and evaluation of factors predicting their malignant potential in patients with colorectal cancer.

Authors:  Mizelle D'Silva; Jai Young Cho; Ho-Seong Han; Taupyk Yerlan; Yoo-Seok Yoon; Hae Won Lee; Jun Suh Lee; Boram Lee; Moonhwan Kim
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

10.  Performance of Multiparametric Functional Imaging and Texture Analysis in Predicting Synchronous Metastatic Disease in Pancreatic Ductal Adenocarcinoma Patients by Hybrid PET/MR: Initial Experience.

Authors:  Jing Gao; Xinyun Huang; Hongping Meng; Miao Zhang; Xiaozhe Zhang; Xiaozhu Lin; Biao Li
Journal:  Front Oncol       Date:  2020-02-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.